ProMIS Neurosciences
Phase 1Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine, EpiSelect™, utilizes computational discovery technologies to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.
Founded
2004
Focus
AntibodiesBiologicsDiagnostics
About
Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine, EpiSelect™, utilizes computational discovery technologies to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.
Funding History
3Total raised: $59.5M
PIPE$10.5MUndisclosedMar 15, 2021
Series B$39MUndisclosedDec 15, 2017
Series A$10MUndisclosedJun 15, 2015
Company Info
TypePrivate
Founded2004
LocationToronto, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile